Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

RA CAPITAL MANAGEMENT, L.P.

Aslan Fred

Artiva Biotherapeutics announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Miralles brings over 20 years of biotech leadership experience and previously served on Artiva's Board. The appointment comes as Artiva prepares for Phase 3 registrational trials of its lead program AlloNK in refractory rheumatoid arthritis, with plans to file a BLA in 2029.

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Built for real traders. Not hype. 
? 10+ years of proven Trading Education 
? Live Trade Room + Community
??Lock in Lifetime Access before May 19

Artiva Biotherapeutics Inc. Common Stock (ARTV) Stock Price, Analysis & Trade Signals